UK Women's Health Market Analysis Report 2022 to 2030

UK Women's Health Market Analysis

$ 3999

In the UK, the National Health Service (NHS) provides free medical care to women, as a result, the market size of UK women’s health is predicted to witness an upsurge of about $537 Mn in 2022 with a CAGR of 5.5% and is estimated to reach $824 Mn in 2030. Growing female labour force participation, particularly in the UK, has made a substantial contribution to the market's expansion. The market is segmented by product type and by disease type. Amgen, Allergen, and Merck and Co. are some of the leading players in the women’s health market.

ID: IN10GBPH026 CATEGORY: Pharmaceuticals GEOGRAPHY: UK

Buy Now

UK Women’s Health Market Executive Analysis

The UK women’s health market size is at around $537 Mn in 2022 and is projected to reach $824 Mn in 2030, exhibiting a CAGR of 5.5% during the forecast period. In the UK, the predicted total cost of current healthcare in 2021 is $295.8 Bn, which is a modest increase of 7.4% over expenditures in 2020. In 2021, the portion of GDP assigned to healthcare was approximately 11.9%, which is comparable to the portion in 2020. Organizations in England have received grants totalling more than $2.10 Mn to support creative programs that are enhancing the health of women at work.

In the UK, women have access to free healthcare through the National Health Service (NHS). This includes preventive care, such as mammograms and cervical cancer screenings, as well as treatment for illnesses and conditions. Women can also access specialized services, such as those for pregnancy and childbirth, menopause, and reproductive health. Over the next year, $135.62 Mn will be invested by the government to strengthen the maternal NHS workforce and expand the capacity for neonatal care. In addition, $102 Mn was spent on hiring 100 consultant obstetricians and an extra 1,200 midwives.

UK women's health market report 2022 to 2030

Market Dynamics

Market Growth Drivers

Anaemia, osteoporosis, breast cancer, and menopause are just a few of the disorders that frequently affect women and have led to an increase in the need for medicines to treat them. In the UK, the market for women's health gadgets has expanded as a result of the increasing focus being given to women's healthcare and their rising personal expendable income. Growing female labour force participation, particularly in the UK, has made a substantial contribution to the market's expansion.

Market Restraints

Because of the worldwide lockdown and stringent limitations implemented to prevent the spread of infection among the public, the COVID-19 pandemic has had a negative impact on the industry of women's health in the UK. The adoption of the products is now being constrained by the high prices of clinical services as well as some adverse effects linked to the drugs. A significant threat to the market's expansion is also posed by the UK government's increasingly strict regulations.

Competitive Landscape

Key Players

Bayer AG (UK)
Pfizer Inc (UK)
Amgen (UK)
Allergen
Merck and Co.

Healthcare Policies and Regulatory Landscape

The fund's focus government from 2022 to 2025 in the UK will be on women's reproductive health at work. This fund, which is connected to the development of the new women's health strategy, seeks to provide financial support to organizations that can offer comprehensive services to help women who are dealing with reproductive health issues, such as menopause, fertility issues, miscarriage, and menstrual health issues, and gynaecological conditions to remain in or return to their jobs. This initiative is a part of the theme funded by the joint project of NHS England, the UK Health Security Agency, the Department of Health and Social Care the Voluntary, Community and Social Enterprise (VCSE) Health and Wellbeing Fund.

Reimbursement Scenario

The National Health Service in the UK provides free medical care to women. This indicates that the majority of healthcare services, particularly those pertaining to women's health, are given to patients without charging a fee. There are a few exclusions, such as prescription fees for a few drugs and a few medical procedures that are not covered by the NHS. The price of these extra services might be partially or entirely covered by private health insurance. The sorts of services they cover and the scope of coverage can differ amongst these policies.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UK Women's Health Market Segmentation

By Product Type (Revenue, USD Billion):

Devices
Drugs

By Application (Revenue, USD Billion):

Contraceptives
Postmenopausal Osteoporosis
Hormonal Infertility
Menopause
Endometriosis
Polycystic Ovary Syndrome (PCOS)
Others

By End-Users (Revenue, USD Billion):

Hospitals & Clinics
Obstetrics & Gynaecology Centers
Ambulatory Surgical Centers
Research Institutes
Others

By Drug (Revenue, USD Billion):

EVISTA
XGEVA
Prolia
Mirena
Zometa
Reclast/Aclasta
Minastrin 24 Fe
NuvaRing
FORTEO
Premarin
ACTONEL
ORTHO TRI-CY LO (28)

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.